

February 26, 2015



Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March 5, 2015

- Conference call with investment community to follow at 8:30 a.m. EST -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that the Company will report its financial results for the fourth quarter and year-end 2014, on Thursday, March 5, 2015 prior to a conference call with the investment community, scheduled at 8:30 a.m. EST.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, <http://ir.navidea.com>, approximately two to four hours after the live event.

Event: Navidea Biopharmaceuticals Q4 and Year-End 2014 Financial Results Conference Call
Date/Time: Thursday, March 5, 2015 at 8:30 a.m. EST

Webcast Link: <http://edge.media-server.com/m/p/wnxb6jnn/lan/en>

Dial-in Number –
US: 1-(800) 708-4540

Dial in Number –
Int'l: 1 (847) 619-6397

Participant
Passcode: 39040655

Replay A webcast replay will be available on the Investor Relations section of our website at <http://ir.navidea.com> for 30 days.

About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a commercial stage precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents. Navidea is developing multiple precision-targeted products and platforms including Manocept™, NAV4694, and NAV5001, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. [Lymphoseek®](#) (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and by the EMA in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company's pipeline through global partnering and commercialization efforts. For more

information, please visit www.navidea.com.

Navidea Biopharmaceuticals

Brent Larson, 614-822-2330

Executive VP & CFO

or

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.